214 related articles for article (PubMed ID: 12017345)
1. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
Metz DC; Ferron GM; Paul J; Turner MB; Soffer E; Pisegna JR; Bochenek WJ
J Clin Pharmacol; 2002 May; 42(5):512-9. PubMed ID: 12017345
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
Ferron GM; McKeand W; Mayer PR
J Clin Pharmacol; 2001 Feb; 41(2):149-56. PubMed ID: 11210394
[TBL] [Abstract][Full Text] [Related]
5. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
6. Continuing development of acid pump inhibitors: site of action of pantoprazole.
Shin JM; Besancon M; Prinz C; Simon A; Sachs G
Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
[TBL] [Abstract][Full Text] [Related]
7. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
8. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
Postius S; Bräuer U; Kromer W
Life Sci; 1991; 49(14):1047-52. PubMed ID: 1832475
[TBL] [Abstract][Full Text] [Related]
9. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
[TBL] [Abstract][Full Text] [Related]
10. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
11. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
12. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
[TBL] [Abstract][Full Text] [Related]
13. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
Simon B; Müller P; Bliesath H; Lühmann R; Hartmann M; Huber R; Wurst W
Aliment Pharmacol Ther; 1990 Jun; 4(3):239-45. PubMed ID: 1966542
[TBL] [Abstract][Full Text] [Related]
14. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole.
Hartmann M; Ehrlich A; Fuder H; Lühmann R; Emeklibas S; Timmer W; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1998 Oct; 12(10):1027-32. PubMed ID: 9798809
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
[TBL] [Abstract][Full Text] [Related]
17. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC
Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.
Tutuian R; Katz PO; Bochenek W; Castell DO
Aliment Pharmacol Ther; 2002 Apr; 16(4):829-36. PubMed ID: 11929403
[TBL] [Abstract][Full Text] [Related]
19. Pantoprazole, Prout and the proton pump.
Playford RJ; Podas T; Modlin I
Hosp Med; 1999 Jul; 60(7):500-4. PubMed ID: 10605542
[TBL] [Abstract][Full Text] [Related]
20. The basis of differentiation of PPIs.
Sachs G; Shin JM
Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
